Lipella is a privately-owned biotech firm specializing in supportive care for cancer survivors who develop hemorrhagic cystitis, as well as enhanced monitoring and imaging for patients with a prior history of transitional cell carcinoma. LP-10 (liposomal tacrolimus), our main product, is currently undergoing clinical trials for the treatment of hemorrhagic cystitis. We are continuously developing new proprietary 505(b)(2) assets to address severe conditions with inadequate existing treatments, and have a range of potential candidates in our pipeline.
Lipella Pharmaceuticals
Headquarters
United States of America